Literature DB >> 32200421

Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer.

Ruochen Li1, Heng Zhang1, Yifan Cao1, Xin Liu2, Yifan Chen3, Yangyang Qi3, Jieti Wang4, Kuan Yu1, Chao Lin1, Hao Liu1, Hongyong He1, He Li1, Lingli Chen5, Zhenbin Shen1, Jing Qin1, Weijuan Zhang3, Yihong Sun6, Jiejie Xu7.   

Abstract

With dichotomous etiology and pathogenesis, intestinal type and diffuse type gastric cancers vary in their clinical and molecular features to the point of representing distinct entities. However, the differences of tumor-infiltrating immune cells within the two types of gastric cancer have not been well researched. This study was aimed to evaluate the functional impact of Lauren classification on immune contexture in gastric cancer patients. Tumor tissues of gastric cancer patients from Zhongshan Hospital and gastric cancer data from The Cancer Genome Atlas (TCGA) cohort were analyzed. By immunohistochemistry and flow cytometry, we found that intratumoral CD8+ T cells were more abundant but less functional in diffuse type as compared with those in intestinal type tumor tissues. Survival analysis indicated that CD8+ T cells yielded favorable prognosis only in intestinal type patients other than diffuse type cancer patients. Moreover, such diffuse type-associated CD8+ T cell dysfunction was featured by elevated expression of immunosuppressive factors including interleukin-10 (IL-10), transforming growth factor-β1 (TGF-β1) and indoleamine 2,3-dioxygenase 1 (IDO1). In summary, we found that the density, prognostic significance and functional status of intratumoral CD8+ T cells varied with Lauren subtypes in gastric cancer. These results further indicated Lauren classification might be a potential therapeutic marker, and should be considered in therapeutic decisions, especially immunotherapeutic eligibility.

Entities:  

Keywords:  CD8+ T cells; Gastric cancer; Lauren classification; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 32200421     DOI: 10.1007/s00262-020-02550-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

1.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.

Authors:  Padmanee Sharma; Yu Shen; Sijin Wen; Sachiko Yamada; Achim A Jungbluth; Sacha Gnjatic; Dean F Bajorin; Victor E Reuter; Harry Herr; Lloyd J Old; Eiichi Sato
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

Review 2.  Immunological battlefield in gastric cancer and role of immunotherapies.

Authors:  Minyu Wang; Rita A Busuttil; Sharon Pattison; Paul J Neeson; Alex Boussioutas
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Histochemical demonstration of hydroxysteroid dehydrogenase activity in the mature canine ovary.

Authors:  E H Fowler; M K Feldman
Journal:  Gen Comp Endocrinol       Date:  1970-06       Impact factor: 2.822

4.  [Acute paroxysmal attack (decompensation) in the initial stage of primary glaucoma].

Authors:  B L Poliak; E N Indeĭkin
Journal:  Vestn Oftalmol       Date:  1969 Nov-Dec

5.  The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.

Authors:  Xi Cheng; Shan Yu; Yan Wang; Yuehong Cui; Wei Li; Yiyi Yu; Cheng Tang; Huiqin Jiang; Yuan Ji; Yihong Sun; Xuefei Wang; Zhenbin Shen; Fenglin Liu; Tian-Shu Liu
Journal:  Gastric Cancer       Date:  2018-11-13       Impact factor: 7.370

Review 6.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

Authors:  Priti S Hegde; Vaios Karanikas; Stefan Evers
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

Review 7.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

8.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

Authors:  Adil I Daud; Kimberly Loo; Mariela L Pauli; Robert Sanchez-Rodriguez; Priscila Munoz Sandoval; Keyon Taravati; Katy Tsai; Adi Nosrati; Lorenzo Nardo; Michael D Alvarado; Alain P Algazi; Miguel H Pampaloni; Iryna V Lobach; Jimmy Hwang; Robert H Pierce; Iris K Gratz; Matthew F Krummel; Michael D Rosenblum
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

9.  Lauren classification and individualized chemotherapy in gastric cancer.

Authors:  Junli Ma; Hong Shen; Linda Kapesa; Shan Zeng
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

10.  Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.

Authors:  Paula Jiménez Fonseca; Alberto Carmona-Bayonas; Raquel Hernández; Ana Custodio; Juana Maria Cano; Alejandra Lacalle; Isabel Echavarria; Ismael Macias; Monserrat Mangas; Laura Visa; Elvira Buxo; Felipe Álvarez Manceñido; Antonio Viudez; Carles Pericay; Aitor Azkarate; Avinash Ramchandani; Carlos López; Eva Martinez de Castro; Ana Fernández Montes; Federico Longo; Rodrigo Sánchez Bayona; Maria Luisa Limón; Asun Diaz-Serrano; Alfonso Martin Carnicero; David Arias; Paula Cerdà; Fernando Rivera; Jose Maria Vieitez; Manuel Sánchez Cánovas; M Garrido; J Gallego
Journal:  Br J Cancer       Date:  2017-08-01       Impact factor: 7.640

View more
  9 in total

1.  CD103+ T Cells May Be a Useful Biomarker in Borrmann Type 4 Gastric Cancer.

Authors:  Takuya Mori; Hiroaki Tanaka; Sota Deguchi; Yuichiro Miki; Mami Yoshii; Tatsuro Tamura; Takahiro Toyokawa; Shigeru Lee; Kazuya Muguruma; Masaichi Ohira
Journal:  Cancer Diagn Progn       Date:  2022-05-03

Review 2.  IDO Expression in Cancer: Different Compartment, Different Functionality?

Authors:  Annabel Meireson; Michael Devos; Lieve Brochez
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

3.  Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer.

Authors:  Xin Yin; Tianyi Fang; Yimin Wang; Yufei Wang; Daoxu Zhang; Chunfeng Li; Yingwei Xue
Journal:  Cancer Med       Date:  2021-01-06       Impact factor: 4.452

Review 4.  Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.

Authors:  Bhalchandra Mirlekar
Journal:  SAGE Open Med       Date:  2022-01-25

Review 5.  The dawn of precision medicine in diffuse-type gastric cancer.

Authors:  Akira Ooki; Kensei Yamaguchi
Journal:  Ther Adv Med Oncol       Date:  2022-03-08       Impact factor: 8.168

Review 6.  Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Authors:  Cristina Díaz Del Arco; Luis Ortega Medina; Lourdes Estrada Muñoz; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Histol Histopathol       Date:  2021-02-10       Impact factor: 2.303

7.  Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients.

Authors:  Quan Jiang; Jie Sun; Hao Chen; Chen Ding; Zhaoqing Tang; Yuanyuan Ruan; Fenglin Liu; Yihong Sun
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

Review 8.  Recent advances in immune therapies for gastric cancer.

Authors:  Matthew J Olnes; Holly A Martinson
Journal:  Cancer Gene Ther       Date:  2021-03-04       Impact factor: 5.987

9.  Clinical Relevance of the Tumor Location-Modified Laurén Classification System for Gastric Cancer in a Western Population.

Authors:  J L Moore; A R Davies; A Santaolalla; M Van Hemelrijck; N Maisey; J Lagergren; J A Gossage; M Kelly; C R Baker
Journal:  Ann Surg Oncol       Date:  2022-01-18       Impact factor: 4.339

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.